AP2005003263A0 - Pyrazole derivatives as transforming growth factor(TGF) inhibitors. - Google Patents

Pyrazole derivatives as transforming growth factor(TGF) inhibitors.

Info

Publication number: AP2005003263A0
Authority: AP; ARIPO
Prior art keywords: tgf; inhibitors; growth factor; transforming growth; pyrazole derivatives
Prior art date: 2002-09-18

Application number

AP2005003263A

Other languages

English (en)

Inventor

Michael John Munchhof

Laura Cook Blumberg

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-18

Filing date

2003-09-08

Publication date

2005-03-31

2003-09-08 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-03-31 Publication of AP2005003263A0 publication Critical patent/AP2005003263A0/xx

Links

102000009618 Transforming Growth Factors Human genes 0.000 title 2
108010009583 Transforming Growth Factors Proteins 0.000 title 2
239000003112 inhibitor Substances 0.000 title 1
150000003217 pyrazoles Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AP2005003263A 2002-09-18 2003-09-08 Pyrazole derivatives as transforming growth factor(TGF) inhibitors. AP2005003263A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41214602P	2002-09-18	2002-09-18
US48454303P	2003-07-02	2003-07-02
PCT/IB2003/003933 WO2004026306A2 (en)	2002-09-18	2003-09-08	Pyrazole derivatives as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number	Publication Date
AP2005003263A0 true AP2005003263A0 (en)	2005-03-31

Family

ID=32033585

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2005003263A AP2005003263A0 (en)	2002-09-18	2003-09-08	Pyrazole derivatives as transforming growth factor(TGF) inhibitors.

Country Status (27)

Country	Link
US (4)	US6958354B2 (de)
EP (2)	EP2165708A3 (de)
JP (1)	JP4519657B2 (de)
KR (1)	KR20050044807A (de)
CN (1)	CN1681501A (de)
AP (1)	AP2005003263A0 (de)
AR (1)	AR041272A1 (de)
AT (1)	ATE450258T1 (de)
AU (1)	AU2003259475A1 (de)
BR (1)	BR0314302A (de)
CA (1)	CA2496295C (de)
CO (1)	CO5550456A2 (de)
DE (1)	DE60330362D1 (de)
EA (1)	EA200500377A1 (de)
EC (1)	ECSP055679A (de)
ES (1)	ES2335099T3 (de)
HR (1)	HRP20050247A2 (de)
IS (1)	IS7698A (de)
MA (1)	MA27440A1 (de)
MX (1)	MXPA05002376A (de)
NO (1)	NO20050838L (de)
OA (1)	OA12929A (de)
PA (1)	PA8583201A1 (de)
PE (1)	PE20040988A1 (de)
PL (1)	PL375979A1 (de)
UY (1)	UY27985A1 (de)
WO (1)	WO2004026306A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL375979A1 (en) *	2002-09-18	2005-12-12	Pfizer Products Inc.	Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026863A1 (en)	2002-09-18	2004-04-01	Pfizer Products Inc.	Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
HRP20050252A2 (en)	2002-09-18	2005-10-31	Pfizer Products Inc.	Novel imidazole compounds as transforming growth factor (tfg) inhibitors
CL2004000234A1 (es) *	2003-02-12	2005-04-15	Biogen Idec Inc	Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PA8595001A1 (es) *	2003-03-04	2004-09-28	Pfizer Prod Inc	Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313915D0 (en) *	2003-06-16	2003-07-23	Smithkline Beecham Corp	Compounds
AU2005280167A1 (en) *	2004-08-31	2006-03-09	Biogen Idec Ma Inc.	Pyrimidinylpyrazoles as TGF-beta inhibitors
WO2006028029A1 (ja) *	2004-09-07	2006-03-16	Sankyo Company, Limited	置換ビフェニル誘導体
AU2005295734A1 (en) *	2004-10-15	2006-04-27	Biogen Idec Ma Inc.	Methods of treating vascular injuries
TW200639163A (en) *	2005-02-04	2006-11-16	Genentech Inc	RAF inhibitor compounds and methods
BRPI0619966A2 (pt) *	2005-12-16	2011-10-25	Alcon Inc	controle de pressão intra-ocular usando agentes de modulação de alk5
KR101107800B1 (ko)	2006-10-31	2012-01-25	화이자 프로덕츠 인코포레이티드	무기질코르티코이드 수용체 길항제로서의 피라졸린 화합물
CN101815712A (zh)	2007-08-01	2010-08-25	辉瑞有限公司	吡唑化合物及其作为raf抑制剂的用途
HUE050761T2 (hu)	2014-01-01	2021-01-28	Medivation Tech Llc	Vegyületek és alkalmazási eljárások
US10822337B2 (en)	2015-04-01	2020-11-03	Rigel Pharmaceuticals, Inc.	TGF-β inhibitorC
WO2016210292A1 (en)	2015-06-25	2016-12-29	Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017161001A1 (en)	2016-03-15	2017-09-21	Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion
WO2017215506A1 (zh)	2016-06-13	2017-12-21	南京明德新药研发股份有限公司	作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
CA3039220A1 (en) *	2016-10-26	2018-05-03	Icahn School Of Medicine At Mount Sinai	Method for increasing cell proliferation in pancreatic beta cells, treatment method, and composition
WO2018086609A1 (zh)	2016-11-14	2018-05-17	江苏恒瑞医药股份有限公司	3,4-二吡啶基吡唑类衍生物、其制备方法及其在医药上的应用
US11547712B2 (en)	2017-11-20	2023-01-10	Icahn School Of Medicine At Mount Sinai	Kinase inhibitor compounds and compositions and methods of use
CN111479809B (zh) *	2017-12-13	2021-10-29	劲方医药科技(上海)有限公司	一种TGF-βRI抑制剂的晶型、盐型及其制备方法
CN111819193A (zh)	2018-01-05	2020-10-23	西奈山伊坎医学院	增加胰腺β细胞增殖的方法、治疗方法以及组合物
AU2019240065A1 (en)	2018-03-20	2020-09-24	Icahn School Of Medicine At Mount Sinai	Kinase inhibitor compounds and compositions and methods of use
WO2020003219A1 (en) *	2018-06-29	2020-01-02	Oat & Iil India Laboratories Private Limited	Substituted pyrazole derivatives as insecticides and fungicides
EP3886854A4 (de)	2018-11-30	2022-07-06	Nuvation Bio Inc.	Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung
CN113195467A (zh)	2018-12-11	2021-07-30	施万生物制药研发Ip有限责任公司	适用作alk5抑制剂的萘啶和喹啉衍生物
CN110467601B (zh) *	2019-08-29	2021-07-02	杭州市西溪医院	一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用
EP4061809A1 (de)	2019-11-22	2022-09-28	Theravance Biopharma R&D IP, LLC	Substituierte 1,5-naphthyridine oder chinoline als alk5-inhibitoren
EP4065572A1 (de)	2019-11-28	2022-10-05	Origo Biopharma, S.L.	Benzamidderivate als inhibitoren der transformation des wachstumsfaktor-beta-rezeptors i/alk5
EP3978487A1 (de)	2020-09-30	2022-04-06	Origo Biopharma, S.L.	2-(3-pyridin-2-yl-4-chinolin-4-yl-pyrazol-1-yl)-acetamid-derivate als inhibitoren des transformierenden wachstumsfaktor-beta-rezeptors i/alk5

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE640616A (de)	1962-12-19
US3492397A (en)	1967-04-07	1970-01-27	Warner Lambert Pharmaceutical	Sustained release dosage in the pellet form and process thereof
US4060598A (en)	1967-06-28	1977-11-29	Boehringer Mannheim G.M.B.H.	Tablets coated with aqueous resin dispersions
US3538214A (en)	1969-04-22	1970-11-03	Merck & Co Inc	Controlled release medicinal tablets
US4173626A (en)	1978-12-11	1979-11-06	Merck & Co., Inc.	Sustained release indomethacin
US4925857A (en) *	1989-03-22	1990-05-15	Sterling Drug Inc.	Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents
JP3734180B2 (ja) *	1994-12-28	2006-01-11	エーザイ株式会社	新規ピラゾール誘導体
AU7726898A (en)	1997-05-22	1998-12-11	G.D. Searle & Co.	Pyrazole derivatives as p38 kinase inhibitors
PL336990A1 (en)	1997-05-22	2000-07-31	Searle & Co	3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
US6514977B1 (en)	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
DE60001229T2 (de)	1999-04-09	2003-10-30	Smithkline Beecham Corp., Philadelphia	Triarylimidazole
CO5271680A1 (es)	2000-02-21	2003-04-30	Smithkline Beecham Corp	Compuestos
GB0007405D0 (en)	2000-03-27	2000-05-17	Smithkline Beecham Corp	Compounds
PE20020506A1 (es)	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
WO2002040468A1 (en)	2000-11-16	2002-05-23	Smithkline Beecham Corporation	Compounds
GB0027987D0 (en)	2000-11-16	2001-01-03	Smithkline Beecham Plc	Compounds
GB0100762D0 (en)	2001-01-11	2001-02-21	Smithkline Beecham Plc	Novel use
GB0102672D0 (en) *	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
WO2002062787A1 (en) *	2001-02-02	2002-08-15	Glaxo Group Limited	Pyrazoles as tgf inhibitors
JP2004521915A (ja) *	2001-02-02	2004-07-22	グラクソ　グループ　リミテッド	Ｔｇｆ過剰発現に対するピラゾール誘導体
ES2251582T3 (es)	2001-03-09	2006-05-01	Pfizer Products Inc.	Compuestos antiinflamatorios de bencimidazol.
DE60227794D1 (de)	2001-04-26	2008-09-04	Eisai R&D Man Co Ltd	Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
AR039241A1 (es)	2002-04-04	2005-02-16	Biogen Inc	Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2004013135A1 (en)	2002-07-31	2004-02-12	Smithkline Beecham Corporation	2-phenylpyridin-4-yl derivatives as alk5 inhibitors
WO2004026863A1 (en)	2002-09-18	2004-04-01	Pfizer Products Inc.	Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
AU2003260810A1 (en)	2002-09-18	2004-04-08	Pfizer Products Inc.	Triazole derivatives as transforming growth factor (tgf) inhibitors
HRP20050252A2 (en)	2002-09-18	2005-10-31	Pfizer Products Inc.	Novel imidazole compounds as transforming growth factor (tfg) inhibitors
PL375979A1 (en)	2002-09-18	2005-12-12	Pfizer Products Inc.	Pyrazole derivatives as transforming growth factor (tgf) inhibitors
CN1681809A (zh)	2002-09-18	2005-10-12	辉瑞产品公司	作为转化生长因子(tgf)抑制剂的新的异噻唑和异噁唑化合物
PA8595001A1 (es)	2003-03-04	2004-09-28	Pfizer Prod Inc	Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)

2003
- 2003-09-08 PL PL03375979A patent/PL375979A1/xx not_active Application Discontinuation
- 2003-09-08 AU AU2003259475A patent/AU2003259475A1/en not_active Abandoned
- 2003-09-08 EA EA200500377A patent/EA200500377A1/ru unknown
- 2003-09-08 ES ES03797443T patent/ES2335099T3/es not_active Expired - Lifetime
- 2003-09-08 JP JP2004568904A patent/JP4519657B2/ja not_active Expired - Fee Related
- 2003-09-08 BR BR0314302-3A patent/BR0314302A/pt not_active IP Right Cessation
- 2003-09-08 CA CA2496295A patent/CA2496295C/en not_active Expired - Fee Related
- 2003-09-08 AP AP2005003263A patent/AP2005003263A0/xx unknown
- 2003-09-08 HR HR20050247A patent/HRP20050247A2/hr not_active Application Discontinuation
- 2003-09-08 DE DE60330362T patent/DE60330362D1/de not_active Expired - Lifetime
- 2003-09-08 EP EP09177298A patent/EP2165708A3/de not_active Withdrawn
- 2003-09-08 AT AT03797443T patent/ATE450258T1/de not_active IP Right Cessation
- 2003-09-08 KR KR1020057004598A patent/KR20050044807A/ko not_active Ceased
- 2003-09-08 EP EP03797443A patent/EP1542684B1/de not_active Expired - Lifetime
- 2003-09-08 MX MXPA05002376A patent/MXPA05002376A/es active IP Right Grant
- 2003-09-08 OA OA1200500078A patent/OA12929A/en unknown
- 2003-09-08 CN CNA038222655A patent/CN1681501A/zh active Pending
- 2003-09-08 WO PCT/IB2003/003933 patent/WO2004026306A2/en not_active Ceased
- 2003-09-15 PE PE2003000940A patent/PE20040988A1/es not_active Application Discontinuation
- 2003-09-16 UY UY27985A patent/UY27985A1/es not_active Application Discontinuation
- 2003-09-16 AR ARP030103356A patent/AR041272A1/es unknown
- 2003-09-17 PA PA20038583201A patent/PA8583201A1/es unknown
- 2003-09-17 US US10/667,189 patent/US6958354B2/en not_active Expired - Fee Related
2005
- 2005-02-16 NO NO20050838A patent/NO20050838L/no unknown
- 2005-02-17 IS IS7698A patent/IS7698A/is unknown
- 2005-03-16 EC EC2005005679A patent/ECSP055679A/es unknown
- 2005-03-16 CO CO05024529A patent/CO5550456A2/es not_active Application Discontinuation
- 2005-03-18 MA MA28154A patent/MA27440A1/fr unknown
- 2005-09-23 US US11/234,564 patent/US7151110B2/en not_active Expired - Fee Related
2006
- 2006-11-08 US US11/557,638 patent/US7638537B2/en not_active Expired - Fee Related
2009
- 2009-11-12 US US12/617,027 patent/US20100056571A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1542684B1 (de)	2009-12-02
CA2496295C (en)	2010-11-23
AU2003259475A1 (en)	2004-04-08
ATE450258T1 (de)	2009-12-15
EP1542684A2 (de)	2005-06-22
OA12929A (en)	2006-10-13
CO5550456A2 (es)	2005-08-31
EP2165708A3 (de)	2010-07-28
US6958354B2 (en)	2005-10-25
EA200500377A1 (ru)	2005-08-25
US7151110B2 (en)	2006-12-19
US7638537B2 (en)	2009-12-29
MXPA05002376A (es)	2005-05-23
JP2006507353A (ja)	2006-03-02
UY27985A1 (es)	2004-04-30
CN1681501A (zh)	2005-10-12
CA2496295A1 (en)	2004-04-01
IS7698A (is)	2005-02-17
DE60330362D1 (de)	2010-01-14
US20100056571A1 (en)	2010-03-04
ES2335099T3 (es)	2010-03-22
WO2004026306A2 (en)	2004-04-01
PA8583201A1 (es)	2004-04-23
BR0314302A (pt)	2005-07-05
HRP20050247A2 (en)	2005-10-31
KR20050044807A (ko)	2005-05-12
ECSP055679A (es)	2005-05-30
MA27440A1 (fr)	2005-07-01
US20040116474A1 (en)	2004-06-17
PL375979A1 (en)	2005-12-12
PE20040988A1 (es)	2004-12-25
JP4519657B2 (ja)	2010-08-04
EP2165708A2 (de)	2010-03-24
NO20050838L (no)	2005-05-18
WO2004026306A3 (en)	2004-07-01
US20070117850A1 (en)	2007-05-24
US20060025451A1 (en)	2006-02-02
AR041272A1 (es)	2005-05-11

Publication	Publication Date	Title
AP2005003263A0 (en)	2005-03-31	Pyrazole derivatives as transforming growth factor(TGF) inhibitors.
PL375974A1 (en)	2005-12-12	Triazole derivatives as transforming growth factor (tgf) inhibitors
PL375980A1 (en)	2005-12-12	Novel imidazole compounds as transforming growth factor (tgf) inhibitors
AU2002341195A1 (en)	2003-05-01	Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives
AU2002342675A1 (en)	2003-04-22	Pyrazole derivatives as glycine transporter inhibitors
AU2003292429A1 (en)	2004-07-14	Pyrazole compounds
AU2003271566A1 (en)	2004-03-03	Pyrrolopyrazines as kinase inhibitors
AU2002312883A1 (en)	2003-05-01	Substituted cyclohexane-1,4-diamine derivatives
AU2003249442A1 (en)	2004-02-16	Kinase inhibitors
AU2003222055A1 (en)	2003-10-08	Kinase inhibitors
AU2002305260A1 (en)	2002-11-11	Pyrazole derived kinase inhibitors
AP2005003353A0 (en)	2005-09-30	Diazepinoindole derivatives as kinase inhibitors.
AU2003299651A1 (en)	2004-06-30	Tyrosine kinase inhibitors
SI1385825T1 (sl)	2008-02-29	Substituirani 2-piridin-cikloheksan-1,4-diaminskiderivati
MXPA03006773A (es)	2003-10-24	Derivados de imidazol.
AP2005003198A0 (en)	2005-03-31	Spiroindolinepiperidine derivatives.
ZA200500170B (en)	2006-02-22	Indole-3-sulphur derivatives.
AU2003237446A1 (en)	2003-12-22	Pyrazole-derivatives as p38 kinase inhibitors
AU2003284399A1 (en)	2004-06-03	Plk inhibitors
AU2003254337A1 (en)	2004-02-02	Heterobicyclic pyrazole derivatives as kinase inhibitors
AU2003298942A1 (en)	2004-06-30	Tyrosine kinase inhibitors
AU2003255333A1 (en)	2004-03-03	Pyrazole inhibitors of the transforming growth factor
AU2003275282A1 (en)	2004-04-23	Novel tyrosine kinase inhibitors
AU2003263323A1 (en)	2004-03-29	Quinazolinone derivatives
AU2003273885A1 (en)	2004-04-23	Morpholine-bridged indazole derivatives